Relmada Therapeutics, Inc.

NASDAQ: RLMD · Healthcare · Biotechnology

PublicHQ Coral Gables, FL · Miami-DadeCIK 0001553643Reports USD

#1133 of 1,422 Healthcare companies by revenuetop-quartile growth

EA Score

39D

FH 42DQ 30GM —SS 55

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, Altman-Z · ↓ disclosure history, operating margin

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$57.4M

Employees

as of 2026-08-11

Market cap

$476.2M

as of 2026-08-11

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$13.1k$13.1k2013

Net income-$57.4M-$57.4M2025

Operating income-$59.1M-$59.1M2025

Total assets$94.0M$94.0M2025

Liabilities$7.5M$7.5M2025

Equity$86.5M$86.5M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Relmada Therapeutics, Inc.’s revenue?

Relmada Therapeutics, Inc. booked $13.1k in FY2013 revenue, growing 65% year over year — faster than most Healthcare companies we track, at a -439060.2% net margin.

Peers · Healthcare

Premier Biomedical, Inc.——Wuhan General Group (China), Inc.——Cryomass Technologies Inc.——The Greater Cannabis Company, Inc.14D Evolutionary Genomics, Inc.——First Colombia Gold Corp.——

Neighbors

Miami-Dade →

Palantir Technologies Inc.$4.5B78B+Royal Caribbean Cruises Ltd.$17.9B80B+Carnival Corporation & plc$26.6B72B MasTec, Inc.$14.3B77B+Lennar Corporation$34.2B74B Watsco, Inc.$7.2B73B

Key facts

CEOSergio Traversa

SectorHealthcare

IndustryBiotechnology

HeadquartersCoral Gables, FL

ExchangeNASDAQ: RLMD

Employees17

IPO date2014-06-20

Latest filings

8-K2026-08-06 10-Q2026-08-06 8-K2026-07-28 8-K2026-05-28 10-Q2026-05-12 8-K2026-05-12 DEF 14A2026-04-17 8-K2026-03-20

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.